Replies to post #144500 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

The "timing" language you're pointing to below is not a requirement, it is more akin to an explanation of general practice and boilerplate. It also covers timing before 36 months as well as after 36 months. Not sure that this clarifies your point at all, given company presentations directly on point. Sorry RKM, but I need more info to concur or agree with this notion. I appreciate your thoughts, as always.

[flipper44]

That is not a PR, SEC statement or NWBO presentation (It's a UCLA consent form that made it onto the internet). The trial can go on even after unblinding as an unblinded trial. Unblinding and termination of trial followup are two completely separate things. They have told us for quite some time that approximately 233 OS is when unblinding will occur. If they changed their mind, they should (and I believe would tell us). The likelihood therefore is they ran a bit over, it takes a while to freeze, scrub, data lock and conduct independent analysis. You came here for one specific purpose. To tell us what you think they can do. However, it is not what they said they would do.

[anders2211]

But RK the consent form for patients enrolling in any trial with any biotech company trying to get FDA is completely different than agreed trial endpoints with the FDA. Especially with an unknown outcome at that start of the trial for the whole enlisted patient group. It is not if the data study is cancelled after DCVAX is approved therefore the enlisted patients give their permission. We all know that NWBO has most likely overtaken present SOC by far, it would be madness to wait for another year, especially when statistically it would not matter to have DCVAX approved. IMO